Revalia Bio
New Haven · Founded 2023
About Revalia Bio
At Revalia we make it possible to study human disease directly in living organs, revealing insights into human biology that were previously impossible. By reviving donated human organs with advanced perfusion technology, we generate a new kind of integrated human data that captures the full complexity of human biology. These living organs act as the Rosetta Stone of Human Data because they allow us to align patient history, anatomy, physiology, cellular, and molecular profiles into a single complete picture. Through what we call Human Data Trials, we then transform this information into decision grade evidence on safety, dosing, and efficacy ’ all before putting a single patient at risk. Just as importantly, Human Data Trials create a new path for organ donation when a donor’s organs cannot be used for clinical transplant. This path transforms the loss of one life into discoveries with the potential to unlock the future of medicine and thereby create a lasting legacy for that patient and their family.
Company Facts
- Founded: 2023
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $19.5M
- Funding stage: Seed
- Last round: Seed (Sep 2025)
- Website: https://revaliabio.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/revalia-bio-98799 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.